Stock · AMGN · Healthcare
United States · Large Cap · listed since 1983 · Revenue 12 mo. $38.1B
Price as of 11/06/2026
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Original text from the data provider
Summary
54.1 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €7.3B (2025), it supports €80.8B. The remaining €142.9B of the market value assume it grows 14.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
14.2%
no growth afterwards
Price to operating cash flow 20.1×, above its usual range.
Middle half of 20 quarters: 13.4× to 17.8×, median 14.2×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
3 more unchanged: Revenue, 12 mo., Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 89.06% | 11.52% | Rank 99 |
| Return on capital (Greenblatt) | 88.36% | 32.55% | Rank 87 |
| EBIT margin | 29.06% | 18.31% | Rank 84 |
| FCF margin | 22.05% | 14.12% | Rank 78 |
| Gross margin | 70.80% | 60.99% | Rank 69 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 9.92% | 8.04% | Rank 61 |
| Earnings growth, 3 years per year | 5.51% | 5.44% | Rank 51 |
| Earnings growth, 5 years per year | 2.93% | 7.00% | Rank 36 |
| Sustainable growth (ROE × retained earnings) | 5.06% | 3.66% | Rank 62 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.09% | 2.90% | Rank 51 |
| FCF yield | 3.25% | 3.63% | Rank 41 |
| EV/saleslower is better | 8.02 | 4.03 | Rank 21 |
| EV/EBITlower is better | 27.60 | 21.73 | Rank 35 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 36.29% | 8.66% | Rank 82 |
| Share price, 6 months | 39.29% | 24.27% | Rank 80 |
| Share price, 3 months | 17.17% | 15.42% | Rank 54 |
| Distance from 52-week high | −3.77% | −7.35% | Rank 66 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −0.33% | 0.30% | Rank 56 |
| Change in share countlower is better | 0.18% | 0.00% | Rank 28 |
| Dividend streak in years | 14 | 10 | Rank 72 |
| Price reaction to results, market-adjusted | 4.61% | 0.05% | Rank 83 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 9.56% | 48.40% | Rank 5 |
| Net debt/EBITDAlower is better | 2.69 | 1.11 | Rank 20 |
| Debt to equitylower is better | 6.31 | 0.48 | Rank 1 |
| Volatility, 1 yearlower is better | 29.65% | 31.42% | Rank 64 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 23.0 | 42.6% | 9.5 | 754M | 31.4 |
| 2017 | 22.8 | 43.7% | 10.5 | 735M | 31.5 |
| 2018 | 23.7 | 43.2% | 10.6 | 665M | 27.0 |
| 2019 | 23.4 | 41.4% | 8.5 | 609M | 23.9 |
| 2020 | 25.4 | 36.0% | 9.9 | 590M | 26.7 |
| 2021 | 26.0 | 29.4% | 8.4 | 573M | 25.3 |
| 2022 | 26.3 | 36.3% | 8.8 | 541M | 31.3 |
| 2023 | 28.2 | 28.0% | 7.4 | 538M | 53.7 |
| 2024 | 33.4 | 21.7% | 10.4 | 541M | 48.1 |
| 2025 | 36.7 | 29.1% | 8.1 | 542M | 45.5 |
4 of 7 StockScorer Score rules met · How the score is built
Amgen Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Amgen Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Amgen Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 32.4 | 30.0 |
| P/B ratio | 28.8 | 4.8 |
| Return on equity (ROE) | 89.1% | 11.5% |
| Equity ratio | 9.6% | 48.4% |
| Debt-to-equity (D/E) | 6.31 | 0.48 |
| Dividend yield | 2.2% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| AMGN | Amgen Incthis page | |
| GILD | Gilead Sciences Inc | High8.2 |
| PFE | Pfizer Inc | Medium5.5 |
| MRK | Merck & Company Inc | Medium5.5 |
| BMY | Bristol-Myers Squibb Company | locked |
| ABBV | AbbVie Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.